Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT01339871
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pazopanib — DRUG
    Starting dose 400 mg orally daily of 28 day cycle.
  • Vorinostat — DRUG
    Starting dose 100 mg orally daily of 28 day cycle.

Study Details

The goal of this clinical research study is to find the highest tolerable dose of the combination of pazopanib and vorinostat that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.

Key Dates

Start date
Apr 20, 2011
Status verified
Jun 2017
Primary completion
Jun 7, 2017
Completion
Jun 7, 2017

Study Design

Enrollment
152 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pazopanib + Vorinostat
    Starting doses Pazopanib 400 mg orally daily and Vorinostat 100 mg orally daily

Primary Outcome Measure

Maximum tolerated dose (MTD) of Pazopanib and Vorinostat [ Time Frame: 28 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies